Kiadis Pharma NV represents values of innovation, dedication, and patient-centricity. The company focuses on developing and commercializing cell-based immunotherapies for patients with life-threatening diseases. With a commitment to improving outcomes and quality of life, Kiadis Pharma NV embraces a corporate philosophy built on scientific expertise, collaboration, and ethical practices. By leveraging its proprietary technologies and deep knowledge in cell therapy, Kiadis Pharma NV strives to revolutionize the treatment landscape and provide hope to patients in need. With a strong emphasis on research and development, the company aims to deliver novel and effective therapies that positively impact the lives of individuals worldwide.

Kiadis Pharma NV is primarily present in the Netherlands, as it is a Dutch-based biopharmaceutical company.

Some significant milestones achieved by Kiadis Pharma NV include; obtaining regulatory approvals for their cell-based immunotherapies, such as ATIR101, which help in preventing relapse following a stem cell transplant. Kiadis Pharma NV also successfully completed clinical trials, demonstrating the safety and efficacy of their therapies in treating leukemia and other blood cancers. In addition, the company expanded its product pipeline and entered into strategic collaborations with other industry leaders to advance the development of innovative treatments. These achievements solidify Kiadis Pharma NV's position as a leading player in the field of cell-based immunotherapies for hematopoietic stem cell transplants.

Kiadis Pharma NV, a renowned biopharmaceutical company, has a rich history and compelling background. Founded in 1997, Kiadis Pharma NV specializes in developing innovative immunotherapy treatments for various life-threatening diseases, particularly hematological malignancies and inherited blood disorders. The company focuses on utilizing Natural Killer (NK) cells, which are an essential component of the immune system, to improve patient outcomes. With a strong commitment to research and development, Kiadis Pharma NV has successfully advanced its lead product, ATIR101, through clinical trials for blood cancer patients. As a leading player in the industry, Kiadis Pharma NV continues to pave the way for personalized medicine and strives to address unmet medical needs globally.

The main competitors of Kiadis Pharma NV in the market are other companies that operate in the field of biotechnology and focus on developing innovative cell therapies. These competitors include companies such as Novartis, Kite Pharma, and Adaptimmune Therapeutics. Kiadis Pharma NV competes in the market by leveraging their unique proprietary technology platform, which enables the production of cell-based therapies for the treatment of various diseases, including blood cancers and genetic disorders. Through constant innovation and strategic partnerships, Kiadis Pharma NV aims to differentiate itself and stay at the forefront of the rapidly evolving cell therapy market.

Kiadis Pharma NV is primarily active in the biotechnology and pharmaceutical industries.

The business model of Kiadis Pharma NV focuses on the development and commercialization of innovative cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company aims to harness the potential of natural killer (NK) cells, a type of immune cell, to provide safe and effective therapies for patients. Kiadis Pharma NV's approach involves utilizing its proprietary platform, called NK-CEL, to enhance the therapeutic potential of NK cells and develop off-the-shelf products. By leveraging its expertise in cell therapy and strategic collaborations, Kiadis Pharma NV aims to address the unmet medical needs of patients and improve outcomes in these challenging diseases.

P/E odnos Kiadis Pharma iznosi -4,96.

KUV kompanije Kiadis Pharma iznosi 12,88.

AlleAktien kvalitativni skor za Kiadis Pharma je 4/10.

očekivana Kiadis Pharma promet je 15,52 mil. EUR.

Dobit očekivana Kiadis Pharma je -40,31 mil. EUR.

The Dutch company Kiadis Pharma NV is a biopharmaceutical company specializing in the development and commercialization of new therapies for patients with blood cancer and other life-threatening diseases. The company is listed on the Nasdaq and Euronext Amsterdam. Kiadis Pharma specializes in the research, development, and commercialization of innovative therapies for the treatment of patients with blood cancer and other life-threatening diseases. The company has two main products: ATIR101 and ATIR201. ATIR101 is a cell therapy made from donor cells to protect the graft against graft-versus-host disease (GVHD). This therapy aims to enable a safer and more successful hematopoietic stem cell transplantation (HSCT) for patients suffering from blood cancer and other life-threatening diseases. ATIR201 is an immunotherapy that focuses on the reactivation of the T-cell receptor (TCR). This therapy aims to provide patients who have already undergone HSCT with an improved immune response against cancer cells. In addition to researching therapies, Kiadis has organized investment in the upcoming marketing process of the therapies. This includes identifying partner companies and developing distribution and marketing strategies to commercially market the therapies. Kiadis Pharma also has a research department focused on identifying new compounds to expand its product pipeline. The company works closely with leading academics and scientists to develop new compounds and improve innovative therapies. Kiadis Pharma also has strong partnerships with other companies in the industry to collaboratively research and develop new therapeutic approaches. The company has partnerships with some of the world's leading pharmaceutical and biotech companies such as Sanofi, Genzyme, Servier, and Celgene. Overall, Kiadis Pharma is an innovative company dedicated to researching and developing new therapies for patients with life-threatening diseases. The company has a robust product pipeline and strong partnerships with leading companies in the industry. Kiadis Pharma has the potential to play a significant role in improving the treatment of patients with blood cancer and other life-threatening diseases.

Kiadis Pharma isplaćuje dividendu od 0 EUR raspoređenu preko isplata u toku godine.

Dividenda za Kiadis Pharma trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Kiadis Pharma je NL0011323407.

WKN od Kiadis Pharma je A14VE3.

Oznaka za praćenje akcija kompanije Kiadis Pharma je KDS.AS.

U poslednjih 12 meseci, Kiadis Pharma je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Kiadis Pharma će verovatno isplatiti dividendu od 0 EUR.

Dividendski prinos od Kiadis Pharma trenutno iznosi .

Kiadis Pharma isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Kiadis Pharma je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 EUR. To odgovara dividendnom prinosu od 0 %.

Kiadis Pharma se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Kiadis Pharma od 12. 9. 2024. u iznosu od 0 EUR, morali ste da imate akciju u depou pre Ex-dana 12. 9. 2024..

Isplata poslednje dividende izvršena je 12. 9. 2024..

U godini 2023 kompanija Kiadis Pharma je isplatila 0 EUR kao dividende.

Dividende od Kiadis Pharma se isplaćuju u EUR.